Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab

Clinical Cancer Research

Volumn 19, Issue 9, 2013, Pages 2551-2561

  Coiffier, Bertrand ^a   Li, Weimin ^b   Henitz, Erin D ^c   Karkera, Jayaprakash D ^c   Favis, Reyna ^c   Gaffney, Dana ^c   Shapiro, Alice ^c   Theocharous, Panteli ^b   Elsayed, Yusri A ^c   Van De Velde, Helgi ^b   Schaffer, Michael E ^b   Osmanov, Evgenii A ^h   Hong, Xiaonan ⁱ   Scheliga, Adriana ^j   Mayer, Jiri ^k   Offner, Fritz ^g   Rule, Simon ^f   Teixeira, Adriana ^l   Romejko Jarosinska, Joanna ^m   De Vos, Sven ^d   Crump, Michael ⁿ   Shpilberg, Ofer ^o   Zinzani, Pier Luigi ^p   Cakana, Andrew ^b   Esseltine, Dixie Lee ^e   Mulligan, George ^e   Ricci, Deborah ^c   more..

^a UNIVERSITÉ LYON 1   (France)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MILLENNIUM PHARMACEUTICALS INC   (United States)

^f DERRIFORD HOSPITAL   (United Kingdom)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h Cancer Research Center   (Russian Federation)

ⁱ FUDAN UNIVERSITY   (China)

^j INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^k UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^l CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^m INSTITUTE OF ONCOLOGY   (Poland)

ⁿ UNIVERSITY OF TORONTO   (Canada)

^o RABIN MEDICAL CENTER   (Israel)

^p UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BORTEZOMIB; CARRIER PROTEIN; CD68 ANTIGEN; PROTEIN P27; PROTEOSOME SUBUNIT ALPHA 5; RITUXIMAB; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLICULAR LYMPHOMA; GENE; GENETIC ANALYSIS; GENETIC MODEL; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PSMB1 GENE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HETEROZYGOTE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84877088158     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3069     Document Type: Article

References (45)

1. Rummel M. Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice. J Natl Compr Canc Netw 2010;8 Suppl 6:S1-14.
2. The Non-Hodgkin's Lymphoma Classi fication Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-18.
3. Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advancedstage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006;108:1504-8. (Pubitemid 44321768)
4. Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995;13:140-7.
5. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-69. (Pubitemid 39507628)
6. Di Bella N, Taetle R, Kolibaba K, Boyd T, Raju R, Barrera D, et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood 2010;115:475-80.
7. O'Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J, et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res 2010;16:719-26.
8. Ribrag V, Tilly H, Casasnovas O, Bosly A, Bouabdullah R, Delarue R, et al. Final results of a randomized phase 2 multicenter study of two bortezomib schedules in patients with recurrent or refractory follicular lymphoma. Groupe d'Etude Des Lymphomes De l'Adulte (GELA) study FL-05 [abstract nr 768]. Blood 2010;116:338a.
9. Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol 2011;29:3389-95.
10. De Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 2009;27:5023-30.
11. Craig M, Hanna WT, Cabanillas F, Chen C-S, Parasuraman S,Neuwirth R, et al. Bortezomib in combination with rituximab, cyclophosphamide, and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma: results of a phase 2 study. [abstract nr 2798]. Blood 2010;116:1153a-4a.
12. Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117:2807-12.
13. Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol 2011;12:773-84.
14. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65. (Pubitemid 39166497)
15. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-53. (Pubitemid 29162950)
16. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl BC, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419-28. (Pubitemid 32708698)
17. Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL, et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005;24:344-54. (Pubitemid 40188583)
18. Goy A, Bernstein SH, McDonald A, Pickard MD, Shi H, Fleming MD, et al. Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leuk Lymphoma 2010;51:1269-77.
19. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131-44. (Pubitemid 47208626)
20. Mulligan G,Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, et al. Gene expression pro filing and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007;109:3177-88. (Pubitemid 46572502)
21. Kelley T, Beck R, Absi A, Jin T, Pohlman B, Hsi E. Biologic predictors in follicular lymphoma: importance of markers of immune response. Leuk Lymphoma 2007;48:2403-11. (Pubitemid 350253472)
22. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin- vincristine-prednisone. Clin Cancer Res 2007;13:5784-9. (Pubitemid 47591642)
23. Kraus M, Ruckrich T, Reich M, Gogel J, Beck A, Kammer W, et al. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia 2007;21:84-92. (Pubitemid 44921839)
24. Lichter DI, Danaee H, Pickard MD, Tayber O, Sintchak M, Shi H, et al. Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood 2012;120:4513-6.
25. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008;112:2489-99.
26. Wang SS, Cerhan JR, Hartge P, Davis S, Cozen W, Severson RK, et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 2006;66:9771-80. (Pubitemid 44623679)
27. Hosgood HD III, Purdue MP, Wang SS, Zheng T, Morton LM, Lan Q, et al. A pooled analysis of three studies evaluating genetic variation in innate immunity genes and non-Hodgkin lymphoma risk. Br J Haematol 2011;152:721-6.
28. Binstadt BA, Geha RS, Bonilla FA. IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy. J Allergy Clin Immunol 2003;111:697-703. (Pubitemid 36470236)
29. Wang H, Liu X, Xu B. [Proteasome inhibitor induces apoptosis and influences the expression of Notch1 and NF-kappaB in multiple myeloma RPMI8226 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008;16:531-7.
30. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8. (Pubitemid 34525533)
31. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006;108:2720-5.
32. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B (Method) 1995;57:289-300.
33. Salles G. Is there a role for bortezomib combinations in the management of patients with follicular lymphoma? J Clin Oncol 2011;29:3349-50.
34. Wahlin BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, Sanchez-Verde L, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 2010;16:637-50.
35. Schmidt M, Zantopf D, Kraft R, Kostka S, Preissner R, Kloetzel PM. Sequence information within proteasomal prosequences mediates efficient integration of beta-subunits into the 20 S proteasome complex. J Mol Biol 1999;288:117-28. (Pubitemid 29201508)
36. Murata S, Yashiroda H, Tanaka K. Molecular mechanisms of proteasome assembly. Nat Rev Mol Cell Biol 2009;10:104-15.
37. Chen S, Blank JL, Peters T, Liu XJ, Rappoli DM, Pickard MD, et al. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res 2010;70:4318-26.
38. Zhu YX, Tiedemann R, Shi CX, Yin H, Schmidt JE, Bruins LA, et al. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood 2011;117:3847-57.
39. Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008;14:1561-70. (Pubitemid 351413941)
40. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007;447:859-63. (Pubitemid 46920134)
41. Kraft C, Peter M, Hofmann K. Selective autophagy: ubiquitin-mediated recognition and beyond. Nat Cell Biol 2010;12:836-41.
42. Canioni D, Salles G,Mounier N, Brousse N, Keuppens M, Morchhauser F, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008;26:440-6. (Pubitemid 351171697)
43. Lefebvre ML, Krause SW, Salcedo M, Nardin A. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother 2006;29:388-97. (Pubitemid 44288951)
44. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005;174:817-26. (Pubitemid 40094277)
45. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, et al. The innate mononuclear phagocyte network depletes B-lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004;199:1659-69. (Pubitemid 38821999)